Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Int J Urol ; 22(12): 1084-95, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26303309

RESUMO

Testosterone deficiency can occur in males of all ages. In adult males, it is induced by endogenous testosterone decline through aging and other modifiable factors. Recent publications suggested the importance of the magnitude of longitudinal decline of testosterone from baseline. The baseline level and the longitudinal decline have individual variability influenced by individual factors including digit ratio, CAG repeat of the androgen receptor and sirtuin activity. Regarding treatment for testosterone deficiency, testosterone replacement therapy is the gold standard for the management of testosterone-deficient patients, and it improves three domains of testosterone deficiency symptoms, such as the physical, psychological and sexual domain. Recent reports suggested the importance of modifiable factors in the testosterone decline in addition to aging. Therefore, it might be responsible for the prevention of testosterone deficiency symptoms to maintain testosterone secretion taking account of the modifiable factors. The present article reviews the literature, and introduces contemporary perspectives and management of testosterone deficiency.


Assuntos
Envelhecimento/sangue , Terapia de Reposição Hormonal , Fitoterapia , Neoplasias da Próstata/induzido quimicamente , Testosterona/deficiência , Testosterona/uso terapêutico , Envelhecimento/genética , Animais , Doenças Cardiovasculares/induzido quimicamente , Exercício Físico/fisiologia , Dedos/anatomia & histologia , Terapia de Reposição Hormonal/efeitos adversos , Humanos , Masculino , Panax , Extratos Vegetais/uso terapêutico , Receptores Androgênicos/genética , Fatores de Risco , Sirtuína 1/metabolismo , Testosterona/sangue
2.
PLoS One ; 10(6): e0129111, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26090819

RESUMO

In order to investigate how holmium laser enucleation of the prostate (HoLEP) improves urinary storage symptoms, we assessed blood flow in the urinary bladder mucosa of patients with benign prostatic hyperplasia (BPH) before and after laser surgery. Seventy-four consecutive patients with BPH (median age 69 years, range; 53-88) underwent HoLEP at our institution and are included in this study. We prospectively assessed the International Prostate Symptom Score (IPSS), IPSS-QOL Score, the Overactive Bladder Symptom Score (OABSS), uroflowmetry, and blood flow in the urinary bladder, before and after surgery. Blood flow in the bladder mucosa was measured using the OMEGA FLOW (OMEGAWAVE, Tokyo, Japan) laser Doppler flowmeter. The median volume of the enucleated adenomas was 45.0 g (range: 25.0 to 83.2). The median IPSS improved significantly from 20 (range: 6-35) to 3 (0-22) (p < 0.001; Wilcoxon signed-rank test), as did the storage symptoms score, which decreased from 13 (2-20) to 3 (1-8) (p < 0.001). Median bladder blood flow increased at the trigone from 9.57 ± 0.83 ml/sec to 17.60 ± 1.08 ml/sec. Multiple regression analysis for the improved storage symptom score eliminated all explanatory variables except increased bladder perfusion. The data suggest that HoLEP improves blood flow in the bladder mucosa, which independently leads to the improvement of storage symptoms.


Assuntos
Hólmio , Terapia a Laser , Fluxo Sanguíneo Regional , Ressecção Transuretral da Próstata , Bexiga Urinária/irrigação sanguínea , Idoso , Idoso de 80 Anos ou mais , Humanos , Masculino , Pessoa de Meia-Idade , Mucosa/irrigação sanguínea , Mucosa/diagnóstico por imagem , Hiperplasia Prostática/cirurgia , Resultado do Tratamento , Ultrassonografia , Bexiga Urinária/diagnóstico por imagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA